Free Trial

Kura Oncology Q1 2024 Earnings Report

Kura Oncology logo
$6.17 -0.35 (-5.37%)
As of 04/3/2025 04:00 PM Eastern

Kura Oncology EPS Results

Actual EPS
-$0.59
Consensus EPS
-$0.56
Beat/Miss
Missed by -$0.03
One Year Ago EPS
-$0.50

Kura Oncology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Kura Oncology Announcement Details

Quarter
Q1 2024
Time
After Market Closes

Conference Call Resources

Remove Ads

Kura Oncology Earnings Headlines

StockNews.com Upgrades Kura Oncology (NASDAQ:KURA) to Buy
EU’s Action Takes Aim At US Retirees
Trump's Return Sparks Massive Gold Rush—Is Your 401(k) Ready for the Fallout? With President Trump back and global powers like China, Russia, and even Europe rapidly moving away from the U.S. dollar, central banks and financial giants are frantically buying gold at historic rates. This massive shift threatens your retirement savings with inflation and market instability—potentially worse than 2008. But you can protect yourself today by leveraging a little-known IRS loophole that lets you diversify your IRA or 401(k) into gold—tax-free and penalty-free.
Kura Flat on Developments
See More Kura Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kura Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kura Oncology and other key companies, straight to your email.

About Kura Oncology

Kura Oncology (NASDAQ:KURA), a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

View Kura Oncology Profile

More Earnings Resources from MarketBeat